Table 1. Crossreactivity of K17F antibodies with various apelin and bioactive peptides.

Peptide	Sequence	Crossreactivity, %
K17F	Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	214
pE13F	pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	100
R12F	Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	110
P11F	Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	48.2
R10F	Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	33.8
G5F	Gly-Pro-Met-Pro-Phe	26.7
K16P	Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro	< 0.3
K15M	Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met	< 0.3
AngII		1.1 ± 0.2
AngIII		0.9 ± 0.1
AVP		< 0.03
NPY		< 0.3

Crossreactivity of the binding of pE13F peptide to K17F antibodies with various apelin fragments and peptides determined by RIA, calculated as the percentage of binding of the apelin-related peptides referred to that of pE13F (100%). Values are expressed as means (± SEM) of multiple assays (n ≥ 3). NPY, neuropeptide Y.